What records are connected here?
- Evidence lanes
- 2
- Source years
- 12
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,3Evidence: Smaller human trialsNot a single peptideBrain, nerves and sleep
Not a single peptide: a mixture often looked up alongside peptides.
Cerebrolysin is not a single peptide but a mixture of small peptides and amino acids taken from pig brain, according to a 2023 Cochrane review. It is widely used for stroke in Russia, Eastern Europe, China and other countries.1,2 The Cochrane review of seven randomized trials in acute ischaemic stroke found that it probably makes little or no difference to death, and that it may increase non-fatal serious adverse events.2 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,3,5
| Substance type | Not a single peptide. A 2023 Cochrane review describes Cerebrolysin as a mixture of low-molecular-weight peptides and amino acids derived from pig brain, and FDA’s substance registry records it as a structurally diverse substance.1,2 |
|---|---|
| What it is | A mixture of low-molecular-weight peptides and amino acids derived from pig brain, recorded by FDA’s substance registry as a structurally diverse substance also coded FPF 1070.1,2 |
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3 |
| Human evidence | Randomized trials in acute ischaemic stroke, summarized in a 2023 Cochrane review of seven trials with 1,773 participants that found no benefit on death.2 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids derived from pig brain, described as having possible nerve-protecting properties, according to the 2023 Cochrane review.2
FDA’s substance registry records it as a structurally diverse substance, not a single defined molecule, under the names Cerebrolysin and FPF 1070.1
It has been studied for a possible protective effect on nerve cells after stroke. The Cochrane review describes potential neuroprotective properties but does not establish a mechanism.2
A 2023 Cochrane review found seven randomized trials, with 1,773 participants, of Cerebrolysin or a similar product started within 48 hours of an acute ischaemic stroke.2
It concluded, with moderate certainty, that these products probably make little or no difference to death from any cause, and that Cerebrolysin probably makes little or no difference to the total number of people with serious adverse events.2
Moderate-certainty evidence also pointed to a possible increase in non-fatal serious adverse events with Cerebrolysin. The review judged the risk of bias in most trials to be unclear and noted that the maker supported three of them.2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of Cerebrolysin by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list Cerebrolysin.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Cerebrolysin is not among them.4,5
Its effect on recovery and quality of life after stroke: the trials in the Cochrane review did not report death or dependence at the end of follow-up, or quality of life.2
Which components of the mixture, if any, are active, which the sources reviewed here do not establish.1,2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Cerebrolysin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Cerebrolysin are a bounded selection, not every registration or paper about Cerebrolysin. For the years before Cerebrolysin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Cerebrolysin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Cerebrolysin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; studied in clinical trials. A Cochrane review of seven randomized stroke trials with 1,773 participants found no benefit on death and a possible rise in non-fatal serious adverse events. Cerebrolysin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; studied in clinical trials. A Cochrane review of seven randomized stroke trials with 1,773 participants found no benefit on death and a possible rise in non-fatal serious adverse events. Cerebrolysin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 14, 2026
Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.↗Added to PeptideScanner November 17, 2026Literature metadata · added November 17, 2026
Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.↗Source date November 14, 2026Literature metadata · added November 16, 2026
Cerebrolysin: a review of its use in dementia.↗Source date October 11, 2026Literature metadata · added November 16, 2026
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.↗Source date October 10, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
19 of 21 selected trial records include at least one phase value; 21 of 21 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
26 of 26 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00840671 at 2026-11-16T17:33:14.861Z. Its registry update date was 2010-12-28, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT00868283 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-12-15, and PeptideScanner's reviewed identity mapping was cerebrolysin.
26 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span December 28, 2010 to November 14, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19848437 in Drugs & aging as Journal Article, Review, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 33620612 in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology as Journal Article, Meta-Analysis, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07846488 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗
Literature metadata
PubMed lists PMID 37892776 in Journal of clinical medicine as Journal Article, Review, with publication-date metadata of 2023-10-20 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06339411 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗
Literature metadata
PubMed lists PMID 39832667 in Neuroscience as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-01-19 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04427241 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗
Literature metadata
PubMed lists PMID 23805635 in Vestnik Rossiiskoi akademii meditsinskikh nauk as Journal Article, Review, with publication-date metadata of 2013 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41349847 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Journal Article, Review, with publication-date metadata of 2025-12-03 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06052787 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05821075 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-07-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Cochrane Database of Systematic Reviews · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026